Skip to content

Clinical study on multi-channel therapy of traditional Chinese medicine for refractory tubal infertility

A randomized controlled clinical research to evaluate the pregnancy rate in one year and safety of traditional Chinese medicine multi-channel therapy after laparoscopy for refractory tubal infertility

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200005734
Enrollment
Unknown
Registered
2022-03-17
Start date
2022-03-15
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female infertility

Interventions

Group C:Traditional Chinese medicine oral liquid + pelvic comprehensive therapy + traditional Chinese medicine fumigation+heat sensitive moxibustion
Group B:Traditional Chinese medicine oral liquid + pelvic comprehensive therapy + traditional Chinese medicine fumigation
Group A:Traditional Chinese medicine oral liquid + pelvic comprehensive therapy

Sponsors

Fujian Nanping people's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
23 Years to 40 Years

Inclusion criteria

Inclusion criteria: ? Consistent with the diagnosis of refractory infertility; ? Infertility in line with tubal factors and at least one fallopian tube is unobstructed after hysteroscopy; ? Aged 23-40 years, the man's semen examination was normal; ? Informed consent and willingness to cooperate.

Exclusion criteria

Exclusion criteria: ? Infertility combined with other factors; ? Heart, liver, kidney and other important organ diseases; ? Those who are unable to cooperate due to neurological and mental disorders; ? Those who are allergic to the therapeutic drugs of this study (such as Salvia miltiorrhiza powder injection, amikacin, moxa, etc.) or have clear treatment contraindications; ? Those who refuse treatment and refuse to sign informed consent.

Design outcomes

Primary

MeasureTime frame
Intrauterine pregnancy rate;

Secondary

MeasureTime frame
Recurrence rate of hydrosalpinx;Safety indicators and adverse events / reactions of multi-channel treatment of traditional Chinese Medicine;

Countries

China

Contacts

Public ContactPan Lizhen

Fujian Nanping people's Hospital

panlz6156@aliyun.com18960606587

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026